• Profit after tax up 88% to A$15.0 million
• Royalty revenue from Acadia increased 16% to A$28.3 million
• Initiated Phase 3 trial for NNZ-2591 in Phelan-McDermid syndrome

Neuren Pharmaceuticals Limited, a biopharmaceutical company developing new drug therapies to treat serious neurological disorders, reported its financial results for the half-year ended 30 June 2025. The company's profit after income tax for the period was A$15.0 million, up 88% from A$8.0 million in the prior corresponding period. This was driven by a 16% increase in royalty revenue from Acadia Pharmaceuticals' launch of DAYBUE (trofinetide) for the treatment of Rett syndrome in the United States, which reached A$28.3 million. Acadia provided guidance for full-year 2025 DAYBUE net sales of US$380-405 million, which is expected to translate to full-year royalties of A$62-67 million for Neuren. In addition, Neuren made significant progress with its second drug candidate NNZ-2591, initiating the first US investigational site for a Phase 3 pivotal trial in Phelan-McDermid syndrome. The company also added two new indications, hypoxic-ischemic encephalopathy and SYNGAP1-related disorder, to its NNZ-2591 pipeline. Neuren's strong financial position, with total cash and short-term investments of A$299.5 million as at 30 June 2025, means no additional funding is required to execute the NNZ-2591 Phase 3 program.

Acadia provided guidance for full-year 2025 DAYBUE net sales of US$380-405 million, which is expected to translate to full-year royalties of A$62-67 million for Neuren.